peptidefix

Peptides / PT-141 / United Kingdom

PT-141 in the United Kingdom

Legal status, what it is, and the listed suppliers in the United Kingdom that list it.

Legal status in the United Kingdom

Not an approved medicine. The MHRA products register returns no result for bremelanotide or Vyleesi (checked 2026-09-22).

As understood at 2026-09-22. Verify with the MHRA.

What PT-141 is

PT-141, or bremelanotide, is a synthetic peptide that activates melanocortin receptors, developed out of research on analogues of alpha-melanocyte-stimulating hormone. It is an approved medicine in the United States, sold as Vyleesi, for one specific indication in women. Its earlier development as a nasal spray for erectile dysfunction in men was not the route that reached approval.

Full PT-141 page: targets and research →

Listed suppliers in the United Kingdom

6 of the 10 suppliers we list in the United Kingdom list PT-141. Listed, not endorsed: each row is the supplier’s own stated terms.

Bluewell Peptides United Kingdom All Bluewell products are supplied strictly for laboratory research use only. They are not intended for human consumption, medical use, therapeutic use, diagnostic use, or veterinary use. Imperial Peptides UK United Kingdom In Vitro Research Use Only. Not for human or veterinary consumption. PeptidesUK United Kingdom For research use only. Research Peptide United Kingdom Supplied strictly for research and laboratory use only and not for human or veterinary consumption. UK Peptides United Kingdom All products are sold exclusively for in-vitro research. They are not for human or veterinary use. XL Peptides United Kingdom All products are exclusively sold for research purposes. They are not intended for human use, therapeutic, diagnostic, or clinical application.

Clinical Research

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al. (2019). Obstetrics & Gynecology. human 1,267 premenopausal women with hypoactive sexual desire disorder across two identical phase 3 trials (RECONNECT), randomised, double-blind, placebo-controlled, 24 weeks
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
Clayton AH, Althof SE, Kingsberg S, et al. (2016). Women's Health. human 327 premenopausal women with female sexual dysfunction (efficacy population), randomised to placebo or one of three bremelanotide groups, 12 weeks
Safety Profile of Bremelanotide Across the Clinical Development Program
Clayton AH, Kingsberg SA, Portman D, et al. (2022). Journal of Women's Health. review n/a (pooled safety review of 43 completed studies, about 3,500 participants, phases 1 to 3)
Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study
Safarinejad MR, Hosseini SY (2008). Journal of Urology. human 342 men aged 28 to 59 with erectile dysfunction not responding to sildenafil, randomised to intranasal bremelanotide or placebo